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Abstract
Background: A wide range of diseases show some degree of clustering in families;
family history is therefore an important aspect for clinicians when making risk
predictions. Familial aggregation is often quantified in terms of a familial relative
risk (FRR), and although at first glance this measure may seem simple and
intuitive as an average risk prediction, its implications are not straightforward.
Methods: We use two statistical models for the distribution of disease risk in a
population: a dichotomous risk model that gives an intuitive understanding of the
implication of a given FRR, and a continuous risk model that facilitates a more
detailed computation of the inequalities in disease risk. Published estimates of
FRRs are used to produce Lorenz curves and Gini indices that quantifies the
inequalities in risk for a range of diseases.
Results: We demonstrate that even a moderate familial association in disease
risk implies a very large difference in risk between individuals in the population.
We give examples of diseases for which this is likely to be true, and we further
demonstrate the relationship between the point estimates of FRRs and the
distribution of risk in the population.
Conclusions: The variation in risk for several severe diseases may be larger than
the variation in income in many countries. The implications of familial risk
estimates should be recognized by epidemiologists and clinicians.
Keywords: Familial relative risk; Inequality; Lorenz curve; Gini index; Familial
association
Background
An important factor in the prediction of disease risk is the family history of disease,
as the presence of such a history indicates that the patient has some underlying
susceptibility. If few risk factors for a disease are known, but a familial association
is observed, assessing family history of disease is one of the simplest and most cost-
effective tools for risk prediction. However, the concept of familial risk is not as
simple as it appears. Indeed, relatives may have an increased risk of disease due
to genetic, epigenetic, common environmental/behavioral factors, or a combination
of these. Very often these underlying determinants are unknown. Despite improved
clinical health registries and the rapid development of genetic research methodology,
observed factors explain only a minor proportion of the variation in disease risk
within a given population [1]. For example, having a BRCA mutation increases
the risk of breast cancer dramatically, but can explain only a minor proportion of
all breast cancers [2]. Similarly, an underlying, unobserved heterogeneity in risk is
likely to be important for many diseases [1].
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This failure to explain the causes of complex diseases is currently a matter of
debate. For example, the impact of chance per se in cancer development has been
heavily discussed after being sparked by Tomasetti and Vogelstein, who implied that
a large proportion of cancers are simply due to ’bad luck’ [3, 4]. When the causes
of a disease are unknown, studying its familial aggregation may help us understand
how the risk is distributed in the population due to both observed and unobserved
factors. This is not only important from a scientific point of view; it can also reveal
the consequences of having an affected relative. In practice, this information may
be important for genetic counseling and for follow-up of individuals with a family
history of disease [5].
Familial associations are often quantified in terms of familial relative risks (FRRs).
Generally, the FRR denotes the risk of disease when a family member is affected
compared to the risk level in the general population. Specific types of familial rela-
tionships, like first-degree relatives, parent-child, or siblings might also be of interest.
A familial association has been demonstrated in a wide range of diseases. In the
last decades, FRRs for virtually all cancers have become readily available in the
literature [6]. For breast, colon, and prostate cancer, the risk has been reported to
double when a family member (first-degree relative) has the disease [6–9], and the
risk further increases if several family members are affected. Furthermore, several
autoimmune and neurodegenerative diseases also have a substantial familial associ-
ation [10, 11]. Therefore, understanding the information that is carried by an FRR
is becoming increasingly important.
Fundamentally, we can assume two different points of view when studying famil-
ial associations. One view consists of focusing on observed familial associations in
incidence, e.g., measured as the FRR, which can be calculated immediately from
the data. The other focuses on how the risk varies between families, i.e., rather
than consider summary measures like the FRR in isolation, we can investigate how
the disease risk is distributed across families in the population. Indeed, it is logical
that a familial association of disease risk implies a variation between individuals in
a population. However, the connection between these two views is not immediate
or intuitively easy. It is generally under-appreciated that a risk factor that is cor-
related within a family has to be very strong to produce even a moderate familial
association in disease risk [12–14]. In the present study, we will use different models
to illustrate various possible, potentially surprising, relationships between these two
views.
First, we will study a simple dichotomous risk model, by dividing the population
into two distinct risk groups. All members of a family (e.g., a group of siblings)
belongs to the same risk group. This model provides simple, yet informative illus-
trations of the relationship between observed familial risk and actual differences in
disease risk. If FRRs are available for both one and two affected family members,
then the actual relative risk between the two risk strata, as well as the size of both of
these strata, can be calculated. Next, we will study a slightly more detailed model,
using a continuous distribution for the risk of developing disease. This facilitates
the computation of Lorenz curves and Gini coefficients, which are well established
methods for measuring inequality in wealth in economics. Finally, we discuss the
issues highlighted in the paper, and their implications.
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Methods
Dichotomous risk model
In the dichotomous risk model, we will consider a population that is divided into
two groups: a high-risk group and a low-risk group. The risk is assumed to be
the same for all individuals in the same group, and all individuals from the same
family belongs to the same risk group. Thus, the type of familial relationship is not
considered here. This is a simplification, but provides convenient and illustrative
examples.
The probabilities of belonging to the high- and low-risk groups are q and 1 − q,
respectively. The risk of acquiring a disease, say within a given age, is ph and pl
within these two groups. The individual relative risk (IRR), comparing a high-risk
individual with a low-risk individual is IRR = ph/pl.
The FRR is calculated by considering two people from the same family. That is,
assuming one family member acquired the disease at a given age, we may calculate
the probability that the other family member will acquire the same disease by the
same age. This probability is then divided by the average risk of disease:
FRR1 =
Prob(person develops disease|family member has disease)
Prob(person develops disease)
=
qIRR2 + 1− q
(qIRR + 1− q)2 .
(1)
This formula can be expanded to include a larger family, whose members might
have different disease statuses. For a family with three members, assuming two have
acquired the disease, the FRR is calculated as
FRR2 =
Prob(person develops disease|two family members has disease)
Prob(person develops disease)
=
qIRR3 + 1− q
(qIRR + 1− q)(qIRR2 + 1− q) .
(2)
Both FRR1 and FRR2 depend on the IRR and the size of the risk groups (q).
However, given the IRR, the FRRs are independent of the actual disease risks in
each group, ph and pl.
Continuous risk model
A more detailed description of the risk distribution can be obtained by considering a
risk that varies continuously in the population. Let P be the probability of acquiring
a disease for a given person over a given time interval (say that the disease occurs
before a certain age). This probability is a random variable in that 1) we let P vary
between families, but assume it is identical for members of the same family; 2) P
accounts for all variability in risk between families, hence individuals from the same
family are independent given the family’s risk level. Define E[P ] as the expected
value of P , i.e., the mean risk of acquiring the disease. Thus the risk of acquiring
the disease if one family member is affected is calculated as
Prob(person develops disease|family member has disease)
=
Prob(both family members develop disease)
Prob(family member develops disease)
=
E[Prob(both family members develop disease|familial risk level P )]
E[Prob(person develops disease|familial risk level P )] =
E[P 2]
E[P ]
.
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Here, E[P 2] is the mean risk of two individuals from the same family acquiring the
disease over a given time interval. By dividing by the mean risk of acquiring the
disease, E[P ], the FRR is found as
FRR =
E[P 2]
E[P ]2
= 1 +
V ar[P ]
E[P ]2
= 1 + CV 2, (3)
where CV is the coefficient of variation of P [1, 15, 16]. Since P s distribution is
nonnegative, even a moderate value of CV implies a skewed distribution.
In the examples to come, we will assume a beta distribution for P [17], which is
a very flexible family of distributions. The density on [0, 1] is given by
f(p;α, β) =
pα−1(1− p)β−1
B(α, β)
, α > 0, β > 0
where B(α, β) is the beta function. The expectation of the distribution is given by
E[P ](α, β) =
α
α+ β
. (4)
The squared coefficient of variation is given as
CV2[P ](α, β) =
β
α(α+ β + 1)
. (5)
We wish to measure and understand the skewness of the distribution, that is, how
(un)evenly the risk is distributed across the population. For this, we use published
estimates of FRRs and the life-time risks of the diseases in question, and plug them
into Expressions (3), (4) and (5).
The Lorenz curve highlights the inequality in risk
In parallel to epidemiological studies of the distribution of disease risk, economic
studies have a strong interest in the distribution of wealth. In economic studies,
the Lorenz curve and the Gini index are important measures. The Lorenz curve
often represents the percentage of income in the population earned by a certain
cumulative percentage of the population. If the Lorenz curve is a straight diagonal
line, it represents perfect equality in income. The Gini index is calculated as the area
between the theoretical perfect equality line and the actual Lorenz curve (which is
usually less than 0.5), multiplied by two. Thus, if the Gini index is 0, there is a
perfect equality in income. Despite its usefulness, the Lorenz curve has been much
less used in epidemiological studies [18]. In studies of disease, the Lorenz curve
displays the expected proportion of disease burden carried by the X% at lowest
risk. Intuitively, in a medical setting the Gini index denotes the deviation from
equality in risk, i.e., the Gini index is equal to 0 if all families have the same disease
risk, and the index is 1 if only one family is at risk. That is, the larger the Gini
index, the larger the deviation from equality.
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Results
Dichotomous risk model: Moderate FRRs can imply large differences in risk
Small high-risk groups produce large FRRs
Figure 1a shows both FRR1 and FRR2 plotted against the IRR in a situation where
only q = 1% of the population belongs to the high-risk group, and the IRR varies
from 1 to 20. In this situation, the FRRs are much lower than all the IRR values.
Assuming one affected family member, a doubling of the FRR requires an IRR
of 12.2. Assuming two affected family members leads to a better correspondence
between the FRR and IRR, but the IRR still has to be larger than 5 to produce a
doubling of the FRR. It is perhaps more natural to consider the IRR as a function
of the FRR, since the latter is observable in practice. Such a plot is given in Figure
1b, in which the discrepancies between the two relative risks when one or two family
members are affected are even more pronounced.
Figure 1 revealed two important characteristics. First, the FRR can be substan-
tially different from the IRR. Closely related to this example, Peto et al. described
a mendelian context with a 10-fold increase in the disease risk among carriers of a
dominant genotype (i.e. an IRR = 10), but having a sibling with the disease only
doubled the risk (i.e. a FRR = 2) [19]. Second, the FRR depends strongly on the
number of affected family members, in particular for rare diseases. One example is
testicular cancer, for which the FRR is 6 given one affected brother, and increases
to almost 22 given two affected brothers [20]. Intuitively, if the disease is rare, hav-
ing an increasing number of affected family members will increase the likelihood
of the family actually belonging to the (small) high-risk group of the population.
Notably, the FRR would be reduced if there were additional disease free members
in the family. For rare diseases, however, the main determinant of the FRR is the
number of affected family members, as has been shown for testicular cancer [20].
FRRs may be misleading for common diseases.
Figures 2a and 2b display the relationship between the FRR and the IRR when
q = 0.5. That is, when we assume that 50% of the population belong to the high-risk
group. FRRs assuming one or two affected family members are below 2 irrespective
of the size of the IRR. This is caused by the fact that the disease appears quite
frequently in the population, therefore having a family member with disease does
not provide much information on whether the family is at high or low risk. Although
having more affected family members will increase this likelihood, Figures 2a and
2b show that this increase is not necessarily substantial. Figures 2c and 2d show a
situation in which the high-risk group accounts for 80% of the population (q = 0.8),
i.e., a minority of 20% has lower disease risk. The FRR does not exceed 1.25 in this
situation, irrespective of the size of the IRR.
Figure 3 presents the relationships between FRRs, assuming one or two affected
family members, and the proportion of high-risk individuals q, given an IRR = 20.
The curves peak at very low values of q, illustrating a better correspondence between
the FRR and the IRR when the high-risk group is small. The plots of the IRR in
terms of the FRR (Figures 1b, 2b, and 2d) clearly illustrated that considering the
FRR alone can give a very misleading impression of the true risk distribution in
the population, especially for common diseases.
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Inferences based on published FRRs
For several diseases, estimates of both FRR1 and FRR2 are available in the lit-
erature. Expressions 1 and 2 can then be solved to find both the corresponding
IRR and high-risk proportion, q. In Table 1, these values are given for seven se-
lected cancers. For testicular cancer, the FRR1 = 5.9 and FRR2 = 21.7 translate
into a high-risk group consisting of 1% of the population, which has 30.6 times the
risk of the remaining 99% of the population. For breast cancer, FRR1 = 1.8 and
FRR2 = 2.9 shows that the 10% of the population that make up the high-risk
group has on average 5.2 times the risk of developing the cancer compared with
the remaining 90%. In the dichotomous model, the IRR represents the ratio of the
average risk in the two groups. This is a crude simplification, but Table 1 illus-
trates that it is possible to gain useful information on how risk is distributed in a
population, even when assuming a dichotomous model. However, rather than being
dichotomous, the real risk distribution is likely continuous and skewed [1].
Continuous risk model: Large inequalities in individual risk are likely
The results from the dichotomous model gave an intuitive understanding of the
challenges of handling familial risks. However, in real life, the individual risk may
often vary continuously across the population. This reflects the fact that the in-
dividual risk of most diseases is caused by a combination of several inherited and
environmental factors.
The risk of severe diseases varies more than income in the USA
Parkinson’s disease has a complex etiology, and many factors, both heritable and
non-heritable, could contribute to disease risk. We therefore consider the risk to
vary continuously across the population. The life-time risk of Parkinson’s disease is
approximately 1% (i.e. E[P ] = 0.01) and the FRR has been estimated at 2.3 [11].
We assume that the beta distribution can describe the risk distribution, and use
the approach described above to make inferences about its shape. Solving Equations
(3), (4) and (5), α = 0.75 and β = 74 are obtained. The corresponding Lorenz curve
is shown in Figure 4a, and the Gini index equals 0.55, which implies a very large
variation in individual risk. This is further demonstrated in Figure 4b, which shows
a Manhattan-type skyscraper landscape, with a large variation in the height of
the columns. These heights are simulations from the distribution and resemble the
disease risk of different families.
For Parkinson’s disease, the large variation in risk is not obvious from its moderate
FRR. Indeed, many severe cancers could share similar patterns. For example, in the
USA, cancer of the pancreas (life-time risk of 1.5% and a FRR of 2.19), leukemias
(life-time risk of 0.96% and a FRR of 2.01), and cancer of the stomach (life-time
risk of 1.78% and a FRR of 1.92) all show these features [21, 22], producing Gini
indexes of 0.54, 0.50 and 0.49, respectively.
A further increased FRR would imply an even more skewed risk distribution for
the same level of life-time risk. In Figure 5, we display the risk distribution and
the Lorenz curves when the lifetime risk is E[P ] = 1%, for different FRRs. In this
scenario, even a moderate FRR of 1.5 implies a distribution that is considerably
skewed; the Lorenz curve corresponds to a Gini index of 0.37, and the 10% with
Valberg et al. Page 7 of 17
the highest risk accounts for 26% of the diagnoses. Increasing the FRR to 6 yields
a Gini index of 0.80, and the 10% with the highest risk accounts for 65% of the
diseased. The latter example is similar to testicular cancer, which has a reported
FRR of 5.88 and a life-time risk of 0.9% [20, 23].
Breast cancer has a reported life-time risk of 12% and a FRR of 1.8 [24, 25],
which renders a Gini index of 0.47. The 10% with highest risk accounts for 30%
of the diagnoses, and the mean risk in that 10% is 6.2 times the mean risk in the
remaining 90%. This is similar to what was found in Table 1 and to hypothesized
risk distributions for breast cancer [2, 26].
More common diseases may also have a considerable variation in risk. For example,
diabetes type 2 has a life-time risk of more than 30% in the USA [27] and is estimated
to have a FRR of 2.24 [28]. This yields a Gini index of 0.60, again implying a strong
heterogeneity in the risk of the disease that is not reflected by the moderate FRR.
For this example, it is also intuitive: We know that several risk factors, e.g., body
weight, physical inactivity and particularly genetic factors, are unequally distributed
between families. Evaluating such factors clearly gives a better indication of the
disease risk than the FRR.
As an interesting comparison, the Gini index for income distributions in the Scan-
dinavian countries ranges from 0.25 to 0.27, in the USA it is 0.45, while Lesotho
tops the list at 0.63 [29]. In other words, all the diseases mentioned above show a
variation in individual risk that is larger than the variation in income in the USA.
Extreme risk in the highest percentile
The results from the dichotomous risk model and the graph in Figure 3 suggested
that large FRRs tend to be found for rare diseases. Diabetes type 1 has a prevalence
of about 0.2% among Americans under 20 years of age and an FRR = 12 among
singleton siblings [30]. Diabetes type 1 occurs when the immune system targets
the insulin producing cells in the pancreas. This processes occurs in genetically
susceptible individuals, but it is postulated that environmental effects, such as viral
infections, could contribute to developing the disease. If we consider the risk of
developing diabetes to be E[P ] = 0.2%, we obtain a Gini index of 0.89. In our
model, 25% of the individuals with disease would belong to a group of high-risk
families comprising only 1% of the total population. The median risk among this
1% of high-risk families would be more than 10,000 times higher than the 99%
remaining population.
Discussion
Even when a familial disease association is modest, the variation in individual risk
could be substantial. Using simple statistical models we have shown relationships
between the FRR and the IRR that are intuitively surprising. Even familial disease
risks that are apparently modest, like the doubling of risk in relatives of patients
with breast cancer or colon cancer, imply large variations in risk between families
[31, 32]. It is important that clinicians and epidemiologists are able to recognize the
consequences of these relationships. In particular, even if an FRR is modest, some
families would have a remarkably larger risk of developing the disease than others.
In fact, the risk distribution may be more skewed than the income distributions of
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many countries. This points to a fundamental, and to a large extent unexplained,
variation in risk. This variation occurs due to genetic predispositions, but also envi-
ronmental, and various other sources of variation, including more unspecific, random
variation [1]. Importantly, this unexplained variation in risk may lead to consider-
able selection bias in observational studies [33, 34]. Estimates of FRRs may actually
be used to adjust for this bias, e.g., in Cox proportional hazards models [35].
Using FRRs for counseling is tempting when other tools for predicting individual
risks, such as genetic tests or biomarkers, are lacking. It could also be tempting
to use FRRs to aid in targeted screening [6, 36]. For example, many countries use
family history of colorectal cancer in screening recommendations today [37]. How-
ever, the quantifications of familial associations are often crude, sometimes limited
to one number for a given familial relationship. We emphasize that this FRR could
be deceiving, even for relatively rare diseases. A correct interpretation of the FRR
is therefore crucial. Individuals could suffer from unnecessary worry and testing
if the FRR is misinterpreted. On the other hand, we could also fail to identify
high-risk individuals by putting too much confidence on moderate FRRs, which
are often population averages. In reality, FRRs vary continuously along a number
of parameters. The number of affected family members is of obvious importance,
but the number of healthy members may also provide important information. Fur-
thermore, the aspect of time is essential. The ages at which family members acquire
a disease (or remains disease free) is crucial to determining the level of risk. Taking
these aspects into account is possible, e.g., by using methods from survival analysis
that provides the opportunity to make risk predictions based on the family history
of specific individuals [16, 20, 38]. These detailed FRRs could be more useful for
individualized risk predictions, and could thus contribute to targeted screening as
well as help focus preventive efforts.
Estimated FRRs from epidemiological studies are often taken at face value in
other biomedical disciplines. For example, these estimates are frequently used as
reference values in genome-wide association studies (GWAS’) [39–42], in which the
proportion of the FRRs that can be attributed to specific, or all known risk alleles
are frequently reported. However, methods for estimating FRRs may vary in their
complexity. Thus, the proportion of the FRR explained in GWAS’ is dependent
on the methods used in the epidemiological studies they base their reference on. A
review of the genetics of type 1 diabetes stated that 34 susceptibility loci explained
60% of the variation in risk, based on an estimated FRR reference value of 15 [43].
The review was criticized for using this reference value as it was estimated in a
period when risk was lower than it is presently, and it was suggested that 12 was
a better estimate [44]. Applying this reference value changed the explained vari-
ance to 75%. The criticism was sound, but alternative methods for estimating the
FRR might have produced a different (or more detailed) estimates [16, 20, 38].
Rather than focusing on a single estimate of the FRR, investigating the sensitivity
to different methods and measures of association seems like a good practice. Fur-
thermore, the FRR encompasses much more than merely genetic inheritance. If all
susceptibility alleles could be identified, they would not explain 100% of the familial
risk. Also, a gene with a strong impact on disease susceptibility might only explain
a minor fraction of the FRR, depending on the magnitude of the FRR and the
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population frequency of the allele [45]. Hence, it is not clear what information that
is provided by this measure (proportion of FRR explained), and it seems difficult
to compare it across different diseases.
Interpreting familial risks can be challenging, especially when relating them to
heredity. Even if a mutation gives a high life-time risk of, say 50%, half of the
high-risk individuals would not be expected to develop the disease. Furthermore,
the mutation would only be passed on to half of the individuals in the next genera-
tion, on average. Consequently, many cancers diagnosed in genetically predisposed
individuals would appear to be sporadic (i.e., occurring in individuals without a
family history). Such an argument has been used to suggest that the majority of
hereditary, early-onset breast cancers appears sporadically in the population [46].
In a recent study, Cremers et al. found that the same single-nucleotide polymor-
phisms (SNPs) were associated with an increased risk of both hereditary (defined
as three cancers in first-degree relatives) and sporadic prostate cancer, and con-
cluded that ”hereditary prostate cancer most probably is merely an accumulation
of sporadic prostate cancers” [47]. Although that might be the case, it is possible
to draw the opposite conclusion; that sporadic cancers are, in fact, also inherited.
This underscores the fact that relating the FRR to heredity is not straightforward.
If assessing the degree of heritability is the aim, one should look to other types of
studies, e.g., to twin studies [48, 49]. However, the large variation in risk implied
by even a moderate familial risk is unlikely to be explained by environmental risk
factors correlated in families [12, 13, 50].
Conclusions
We have seen that the interpretation of the FRR depends on the context. First, the
life-time prevalence of the disease is important. The specific definition of the FRR,
in particular the familial relationships that are studied, may also be crucial. Even
if a precise definition of the FRR is given, it may be estimated in several different
ways. If the FRR is calculated to perform risk predictions and genetic counseling, a
detailed FRR based on individual characteristics (i.e. familial histories) is desirable.
In any case, we have shown that even simple FRRs, averaged over the population,
can reveal important information on how the risk is distributed in the population.
Even a moderate FRR may imply a very skewed risk distribution.
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Figure 1 a) The familial relative risk (FRR) as a function of the individual relative risk (IRR) defined in terms of the dichotomous model in Expression (1) and (2), assuming one
or two diseased family members, respectively. b) The IRR as a function of the FRR. 1% of the population belong to the high-risk group (q = 0.1) in both panels.
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Figure 2 a, c) The familial relative risk (FRR) as a function of the individual relative risk (IRR) defined in terms of the dichotomous model in Expression (1) and (2), assuming
one or two diseased family members, respectively. b, d) The IRR as a function of the FRR. 50% (q = 0.5) and 80% (q = 0.8) of the population belong to the high-risk group in
panels a, b) and c, d), respectively.
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Figure 3 The familial relative risk (FRR) as a function of the proportion, q, of the population
belonging to the high-risk group defined in terms of the dichotomous model in Expression (1) and
(2), assuming one or two diseased family members, respectively. The individual relative risk
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Figure 4 The Lorenz curve (a) and 400 samples (b) from a beta distribution resulting from a familial relative risk of 2.3 and E[P ] = 0.01, representing Parkinson’s disease.
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Figure 5 The distribution (a) of a beta distributed variable P , and its corresponding Lorenz curve (b), for three selected familial relative risks (FRRs). The expected value of P is
set to 0.01. The 10% at highest risk (shaded area) account for 26%, 33%, and 65% of the diagnoses in the three scenarios, respectively.
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Table 1 Expressions 1 and 2 solved for the individual relative risk (IRR) and the high-risk proportion q,
according to the familial relative risks (FRRs) given one (FRR1) and two (FRR2) affected relatives.
Estimates for FRR1 and FRR2 are taken from the indicated reference (the level of accuracy given in
the reference is used).
Cancer Familial relationship studied FRR1 FRR2 =⇒ IRR q
Testicular cancer [20] Brothers 5.88 21.71 =⇒ 30.6 0.010
Prostate cancer [51] Brothers 2.96 7.71 =⇒ 12.2 0.027
Colorectal cancer [52] Siblings 2.25 4.25a =⇒ 7.4 0.067
Melanoma [53] FDRs 1.9 4.7a =⇒ 8.2 0.025
Breast cancer [25] Women FDRs 1.80 2.93 =⇒ 5.2 0.10
Hodgkin’s lymphoma [54] FDRs 6 13a =⇒ 22.6 0.030
Non-medullary thyroid cancer [55] FDRs 3.1 23.2a =⇒ 34.2 0.0022
Abbreviations: FRR, familial relative risk; IRR, individual relative risk; FDR, first degree relative.
a ≥ 2 siblings/FDRs is used in the reference.
